Uniphar Group PLC (UPR) - Total Liabilities

Latest as of June 2025: €1.19 Billion EUR ≈ $1.39 Billion USD

Based on the latest financial reports, Uniphar Group PLC (UPR) has total liabilities worth €1.19 Billion EUR (≈ $1.39 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore UPR shareholders equity momentum to track the company's year-over-year net asset growth rate.

Uniphar Group PLC - Total Liabilities Trend (2016–2024)

This chart illustrates how Uniphar Group PLC's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Uniphar Group PLC to measure how efficiently the company converts operating cash flow to free cash.

Uniphar Group PLC Competitors by Total Liabilities

The table below lists competitors of Uniphar Group PLC ranked by their total liabilities.

Company Country Total Liabilities
PixArt Imaging
TWO:3227
Taiwan NT$2.75 Billion
EQ Resources Ltd
AU:EQR
Australia AU$115.21 Million
Five Star Bancorp
NASDAQ:FSBC
USA $4.57 Billion
Panca Anugrah Wisesa Tbk PT
JK:MGLV
Indonesia Rp57.27 Billion
Advanced Power Electronics Corp
TW:8261
Taiwan NT$776.60 Million
Douglas AG
XETRA:DOU
Germany €3.75 Billion
CTT Correios de Portugal SA
LS:CTT
Portugal €5.53 Billion
Huadian Heavy Industries Co
SHG:601226
China CN¥6.08 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Uniphar Group PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Uniphar Group PLC (UPR) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.95 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 3.18 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.76 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Uniphar Group PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Uniphar Group PLC (2016–2024)

The table below shows the annual total liabilities of Uniphar Group PLC from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 €1.01 Billion
≈ $1.19 Billion
+6.07%
2023-12-31 €955.94 Million
≈ $1.12 Billion
+16.43%
2022-12-31 €821.01 Million
≈ $959.85 Million
+18.40%
2021-12-31 €693.43 Million
≈ $810.69 Million
+8.70%
2020-12-31 €637.92 Million
≈ $745.80 Million
+10.04%
2019-12-31 €579.70 Million
≈ $677.73 Million
+14.57%
2018-12-31 €506.00 Million
≈ $591.57 Million
+68.52%
2017-12-31 €300.25 Million
≈ $351.03 Million
+0.82%
2016-12-31 €297.81 Million
≈ $348.18 Million
--

About Uniphar Group PLC

IR:UPR Ireland Medical Distribution
Market Cap
$1.36 Billion
€1.16 Billion EUR
Market Cap Rank
#8984 Global
#10 in Ireland
Share Price
€4.47
Change (1 day)
+0.68%
52-Week Range
€3.42 - €4.92
All Time High
€4.96
About

Uniphar plc, together with its subsidiaries, operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, the Netherlands, and internationally. It operates through three divisions: Uniphar Medtech, Uniphar Pharma, and Uniphar Supply Chain & Retail. The company provides sales, marketing, compliance, and distribution services to medical device manufacturers;… Read more